Skip to main content

Table 3 Antiplatelet and anticoagulant therapy and anti-MPN therapy

From: Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

 

All patients

PV

ET

PMF

Post-PV-MF

Post-ET-MF

MPN-U

p value#

Antiplatelet drugs

 ASSa; n (%)

248

(57.4)

n = 432

92

(67.2)

n = 137

83

(61.5)

n = 135

45

(42.9)

n = 105

11

(61.1)

n = 18

10

(52.6)

n = 19

7

(38.9)

n = 18

0.0026

 P2Y12 antagonista; n (%)

27

(6.4)

n = 425

9

(6.7)

n = 134

13

(9.7)

n = 134

4

(3.9)

n = 104

0

(0)

n = 17

0

(0)

n = 18

1

(5.6)

n = 18

0.4064

Anticoagulants

 VKA; n (%)

43

(9.8)

n = 437

14

(10.1)

n = 138

13

(9.5)

n = 137

6

(5.6)

n = 107

4

(21.1)

n = 19

3

(16.7)

n = 18

3

(16.7)

n = 18

0.1511

 Rivaroxaban; n (%)

8

(1.8)

n = 437

3

(2.2)

n = 138

1

(0.7)

n = 137

4

(3.7)

n = 107

0

(0)

n = 19

0

(0)

n = 18

0

(0)

n = 18

0.6151

 Heparin; n (%)

16

(3.8)

n = 417

4

(3.1)

n = 131

4

(3.1)

n = 131

5

(4.9)

n = 103

2

(11.1)

n = 18

1

(5.9)

n = 17

0

(0)

n = 17

0.4345

Anti-MPN therapyb

 Watch wait; n (%)

226c

(51.7)

n = 437

79

(57.7)

n = 137

72

(52.9)

n = 136

49

(46.2)

n = 106

7

(33.3)

n = 21

6

(31.6)

n = 19

13

(72.2)

n = 18

0.0321

 Hydroxyurea; n (%)

215

(49.2)

n = 437

82

(59.9)

n = 137

67

(49.3)

n = 136

38

(35.9)

n = 106

10

(47.6)

n = 21

9

(47.4)

n = 19

9

(50)

n = 18

0.0151

 Anagrelide; n (%)

66

(15.1)

n = 437

15

(11.0)

n = 137

32

(23.5)

n = 136

11

(10.4)

n = 106

3

(14.3)

n = 21

4

(21.1)

n = 19

1

(5.6)

n = 18

0.0255

 Ruxolitinib; n (%)

87

(19.9)

n = 437

15

(11.0)

n = 137

5

(3.7)

n = 136

43

(40.6)

n = 106

11

(52.4)

n = 21

12

(63.2)

n = 19

1

(5.6)

n = 18

<0.0001

 IMIDe; n (%)

21

(4.8)

n = 437

2

(1.5)

n = 137

0

(0)

n = 136

15

(14.2)

n = 106

2

(9.5)

n = 21

1

(5.3)

n = 19

1

(5.6)

n = 18

<0.0001

 IFNα; n (%)

40

(9.2)

n = 437

12

(8.8)

n = 137

15

(11.0)

n = 136

9

(8.5)

n = 106

2

(9.5)

n = 21

1

(5.3)

n = 19

1

(5.6)

n = 18

0.9681

 SCT; n (%)

20

(4.6)

n = 439

3

(2.2)

n = 139

0

(0)

n = 134

12

(11.1)

n = 108

2

(9.5)

n = 21

2

(10.5)

n = 19

1

(5.6)

n = 18

<0.0001

  1. VKA vitamin K antagonist, WatchWait watchful waiting, SCT stem cell transplantation
  2. #In Fisher’s exact test
  3. aDouble platelet inhibition in n = 20 patients (4.72 %)
  4. bLife-time therapy
  5. c n = 114 patients (26 %) solely had watchful waiting strategy